Hematological malignancy

This page contains recent news articles, when available, and an overview of Hematological malignancy but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Background information on Hematological malignancy

Although hematological malignancies are a form of cancer, they are generally treated by specialists in hematology, although in many hospitals oncology specialists also manage these diseases. ("Hematology/Oncology" is a single subspecialty of Internal Medicine; there are also surgical and radiation oncologists.)

Hematological malignancies are the types of cancer that affect blood, bone marrow and lymph nodes. As the three are intimately connected through the immune system, a disease affecting one of the three will often affect the others as well: although lymphoma is technically a disease of the lymph nodes, it often spreads to the bone marrow, affecting the blood and occasionally producing a paraprotein.

Chromosomal translocations are a common cause of these diseases, while this is uncommon in solid tumors. This leads to a different approach in diagnosis and treatment of hematological malignancies.

News Articles on Hematological malignancy

A Rare Trifocal Presentation of Clostridium septicum Myonecrosis  -  Mar 10, 2008
Ortho SuperSite,11 Infection with C septicum may be associated with colorectal or hematological malignancy, diabetes mellitus, and drug-induced immunosuppression.

Millennium reports promising results for blood cancer drug  -  Mar 13, 2008
Boston Globe,Multiple myeloma is common hematological malignancy. In the United States, more than 55000 people, many of them elderly, have the disease, and about 20000

Publication of Clinical Results Underscores Velcade (Bortezomib ...  -  Mar 13, 2008
PharmaLive.com (press release),Multiple myeloma is the second most common hematological malignancy and although the disease is predominantly a cancer of the elderly (the median age of

Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in ...  -  Nov 28, 2007
Business Wire (press release),Multiple myeloma is the second most common hematological malignancy of adults, accounting for 10% of the diagnoses of hematological malignancies in the

Get ready to take profits in biotech sector  -  Dec 15, 2007
Financial Post,The two most important conferences in the fourth quarter are the Hematological Malignancy conference in December and the JP Morgan health-care conference in

Millennium: pushing for broader use of Velcade  -  Aug 17, 2007
Pharmaceutical Business ReviewMultiple myeloma is the second most common hematological malignancy and predominantly affects the elderly. However, recent statistics indicate a rise in

Pharmion Corporation Reports Net Sales of $65.8 Million for Q2 2007  -  Jul 25, 2007
PR Newswire (press release),...initiate a pivotal registration program in the near term for MGCD0103 either as monotherapy or in combination with Vidaza in a hematological malignancy.

Tractor Ride Against Cancer makes stop in Creston  -  Jun 12, 2007
Creston News Advertiser,The 250 mile journey along Highway 34 is a grassroots effort to raise funds and support for hematological malignancy (blood-related) cancer and solid tumor

Onconova Therapeutics Announces Presentation of Clinical and Non ...  -  Apr 16, 2007
PharmaLive.com (press release),Na has shown broad-spectrum anti-tumor activity against both solid tumors and hematological malignancy in pre-clinical studies, and has demonstrated

ImmunoGen, Inc. Announces Presentation at ASH of Encouraging ...  -  Dec 12, 2006
PipelineReview.com (press release),...in an abstract (abstract #4548) to the ASH meeting on a second TAP compound, AVE9633, in development for the treatment of a hematological malignancy.

PDL BioPharma Presents Preclinical Data on Novel Monoclonal ...  -  Dec 12, 2006
PharmaLive.com (press release),Multiple myeloma is the second most common hematological malignancy in the US, accounting for about 10 percent of all hematologic malignancies and 1 percent

PDL BioPharma Presents Preclinical Data on Novel Monoclonal ...  -  Dec 11, 2006
PR Newswire (press release),About Multiple Myeloma Multiple myeloma is the second most common hematological malignancy in the US, accounting for about 10 percent of all hematologic

Alemtuzumab Appears Promising as First-Line B-cell Chronic ...  -  Dec 11, 2006
DG News...department of clinical hematology and hematological malignancy diagnostic service, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

PDL BioPharma Presents Preclinical Data on Novel Monoclonal ...  -  Dec 12, 2006
PharmaLive.com (press release),Multiple myeloma is the second most common hematological malignancy in the US, accounting for about 10 percent of all hematologic malignancies and 1 percent of ...

Alemtuzumab Appears Promising as First-Line B-cell Chronic ...  -  Dec 11, 2006
DG News...line trial," said lead investigator Peter Hillmen, MD, PhD, program chair, department of clinical hematology and hematological malignancy diagnostic service ...

Early Procrit® Improves Quality of Life in Patients With Mild ...  -  Oct 23, 2006
Cancer Consultants (press release),These authors concluded that early intervention with Procrit was very beneficial in patients with hematological malignancy receiving myelosuppressive ...

Search the web for more resources on Hematological malignancy

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.